8 news items
Alnylam Issues 2023 Corporate Responsibility Report
ALNY
7 May 24
.
Expanded partnerships and strategies to support diversity and inclusion within clinical trials
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
"Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
"Alnylam P5x25" strategy to deliver transformative medicines in both rare and common
m5rdj9t4aia38ifspqrh47na74clinu
ALNY
20 Mar 24
"Alnylam P5x25" strategy to deliver transformative medicines
9rzgag
ALNY
13 Mar 24
P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting
irk7h50fz s4ndw576wzg2vj0e4wbrr8s8t6gf76s61mbl
ALNY
5 Mar 24
is executing on its "Alnylam P5x25" strategy to deliver
- Prev
- 1
- Next